[go: up one dir, main page]

YU47122B - 5-deoksi-5-fluorocitidinski derivati - Google Patents

5-deoksi-5-fluorocitidinski derivati

Info

Publication number
YU47122B
YU47122B YU209188A YU209188A YU47122B YU 47122 B YU47122 B YU 47122B YU 209188 A YU209188 A YU 209188A YU 209188 A YU209188 A YU 209188A YU 47122 B YU47122 B YU 47122B
Authority
YU
Yugoslavia
Prior art keywords
atoms
formula
carbon atoms
fluorocitidinski
deoksi
Prior art date
Application number
YU209188A
Other languages
English (en)
Other versions
YU209188A (en
Inventor
M. Fujiu
H. Ishitsuka
M. Miwa
I. Umeda
K. Yokose
Original Assignee
F. Hoffmann-La Roche & Co. Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche & Co. Ag. filed Critical F. Hoffmann-La Roche & Co. Ag.
Publication of YU209188A publication Critical patent/YU209188A/xx
Publication of YU47122B publication Critical patent/YU47122B/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

5-DEOKSI-5-FLUOROCITIDINSKI DERIVATI, naznačeni time, što imaju opštu formulu (I), u kojoj R1, R2 i R3 nezavisno jedan od drugog označavaju vodonik ili neki radikal koji se lako hidrolizuje pod fiziološkim uslovima i predstavljen je formulom R4CO-, R5OCO- ili R6SCO-u kojoj R4 označava atom vodonika, alkil sa 1-17 C-atoma, cikloalkil sa 3 do 10 C-atoma, alkenil sa 2 do 8 C-atoma, aralkil sa najviše 9 C-atoma ili aril sa najviše 10 C-atoma, dok R5 i R6 označavaju alkil sa 1 do 8 C-atoma ili aralkil sa najviše 9 C-atoma, s tim što bar jedno od R1, R2, R3 mora biti radikal navedene formul, kao i hidrati ili solvata jedinjenja formule.
YU209188A 1987-11-17 1988-11-10 5-deoksi-5-fluorocitidinski derivati YU47122B (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP87116926 1987-11-17

Publications (2)

Publication Number Publication Date
YU209188A YU209188A (en) 1990-08-31
YU47122B true YU47122B (sh) 1994-12-28

Family

ID=8197450

Family Applications (1)

Application Number Title Priority Date Filing Date
YU209188A YU47122B (sh) 1987-11-17 1988-11-10 5-deoksi-5-fluorocitidinski derivati

Country Status (35)

Country Link
US (1) US4966891A (sh)
EP (1) EP0316704B1 (sh)
JP (1) JPH0678350B2 (sh)
KR (1) KR970000241B1 (sh)
CN (1) CN1022688C (sh)
AR (1) AR247217A1 (sh)
AT (1) ATE124951T1 (sh)
AU (1) AU619220B2 (sh)
CA (1) CA1327358C (sh)
CS (1) CS274486B2 (sh)
DE (2) DE10199027I2 (sh)
DK (1) DK170893B1 (sh)
DZ (1) DZ1270A1 (sh)
ES (1) ES2074429T3 (sh)
FI (1) FI89804C (sh)
GR (1) GR3017686T3 (sh)
HK (1) HK1003114A1 (sh)
HU (1) HU199866B (sh)
IE (1) IE883430L (sh)
IL (1) IL88363A0 (sh)
IS (1) IS1895B (sh)
LT (1) LT2185B (sh)
LU (1) LU90769I2 (sh)
LV (1) LV5624A3 (sh)
MC (1) MC1992A1 (sh)
MX (1) MX173347B (sh)
NL (1) NL300045I2 (sh)
NO (2) NO171167C (sh)
NZ (1) NZ226923A (sh)
PH (1) PH25641A (sh)
PT (1) PT89009B (sh)
SU (1) SU1736342A3 (sh)
UA (1) UA19333A (sh)
YU (1) YU47122B (sh)
ZA (1) ZA888428B (sh)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6258360B1 (en) * 1989-05-04 2001-07-10 Igen International, Inc. Prodrugs activated by targeted catalytic proteins
US5527782A (en) * 1990-03-13 1996-06-18 Acic (Canada) Inc. 5-halo-2,3'-O-cyclocytidines
AU671491B2 (en) * 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
TW254946B (sh) * 1992-12-18 1995-08-21 Hoffmann La Roche
US5476932A (en) * 1994-08-26 1995-12-19 Hoffmann-La Roche Inc. Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
IT1291983B1 (it) * 1997-05-23 1999-01-25 Pro Bio Sint Srl Prodcedimento per la preparazione di un derivato della desossiuridina
NZ330360A (en) * 1997-06-02 1999-03-29 Hoffmann La Roche 5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents
EP0882734B1 (en) * 1997-06-02 2009-08-26 F. Hoffmann-La Roche Ag 5'-Deoxy-cytidine derivatives
US6005098A (en) * 1998-02-06 1999-12-21 Hoffmann-La Roche Inc. 5'deoxycytidine derivatives
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
US20010051348A1 (en) * 2000-01-28 2001-12-13 Lee Chee Wee Novel ligands and methods for preparing same
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
EP2316468A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
US6774758B2 (en) * 2002-09-11 2004-08-10 Kalyan P. Gokhale Low harmonic rectifier circuit
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
EP1631278A4 (en) * 2003-05-20 2006-09-20 Aronex Pharmaceuticals Inc COMBINED CHEMOTHERAPY COMPRISING CAPECITABINE AND A COMPLEX BASED ON LIPOSOMIC PLATINUM
ATE402185T1 (de) * 2003-12-22 2008-08-15 Hoffmann La Roche Verfahren für fluorcytidinderivate
CA2554686A1 (en) * 2004-02-18 2005-09-01 Astrazeneca Ab Compounds
AU2005214132B9 (en) * 2004-02-18 2009-06-25 Astrazeneca Ab Benzamide derivatives and their use as glucokinae activating agents
CN100383128C (zh) * 2004-02-23 2008-04-23 上海迪赛诺医药发展有限公司 N4－氧羰基胞嘧啶衍生物及制备方法与应用
TW200600086A (en) 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
KR101061850B1 (ko) 2004-09-08 2011-09-02 삼성전자주식회사 박막 트랜지스터 표시판 및 그 제조방법
GB0421294D0 (en) * 2004-09-24 2004-10-27 Angiogene Pharm Ltd Bioreductively-activated prodrugs
MX2007004560A (es) 2004-10-16 2007-06-08 Astrazeneca Ab Proceso para hacer compuestos de fenoxi benzamida.
GB0423043D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
CN113952459B (zh) 2005-02-03 2025-02-11 综合医院公司 治疗吉非替尼耐药性癌症的方法
NO322682B1 (no) * 2005-03-18 2006-11-27 Clavis Pharma Asa Anvendelse av gemcitabinderivater for fremstilling av orale doseringsformer ved kreftbehandling, samt slike orale doseringsformer
EP1868608A2 (en) * 2005-04-01 2007-12-26 F. Hoffmann-Roche AG Method for administration of capecitabine
EP1891069A1 (en) * 2005-05-24 2008-02-27 AstraZeneca AB 2-phenyl substituted imidazol [4,5b]pyridine/ pyrazine and purine derivatives as glucokinase modulators
TW200714597A (en) 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
EP2027113A1 (en) * 2005-07-09 2009-02-25 AstraZeneca AB Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
JP2009500442A (ja) * 2005-07-09 2009-01-08 アストラゼネカ アクチボラグ ２型糖尿病を処置するためのグルコキナーゼのモジュレーターとしての２−ヘテロシクリルオキシベンゾイルアミノヘテロシクリル化合物
KR20110084339A (ko) 2005-07-09 2011-07-21 아스트라제네카 아베 당뇨병 치료에 있어 ｇｌｋ 활성화제로서 사용하기 위한 헤테로아릴 벤즈아미드 유도체
CN100569790C (zh) * 2005-07-15 2009-12-16 上海奥锐特国际贸易有限公司 合成n4-酰基-5＇-脱氧-5-氟胞苷衍生物的方法
US20080292729A1 (en) * 2005-07-21 2008-11-27 Nuvo Research Inc. Stabilized Chlorite Solutions in Combination with Fluoropyrimidines for Cancer Treatment
US9202182B2 (en) * 2005-08-11 2015-12-01 International Business Machines Corporation Method and system for analyzing business architecture
CN103110948A (zh) 2005-11-04 2013-05-22 惠氏公司 mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合
TW200738621A (en) 2005-11-28 2007-10-16 Astrazeneca Ab Chemical process
US20080085310A1 (en) * 2006-10-06 2008-04-10 Maria Oksana Bachynsky Capecitabine rapidly disintegrating tablets
TW200825063A (en) 2006-10-23 2008-06-16 Astrazeneca Ab Chemical compounds
CL2007003061A1 (es) 2006-10-26 2008-08-01 Astrazeneca Ab Compuestos derivados de 3,5-dioxi-benzamida; proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una enfermedad mediada a traves de glk, tal como la diabetes tipo 2.
CN100425617C (zh) * 2006-10-31 2008-10-15 浙江海正药业股份有限公司 一种含氟嘧啶类化合物烷氧羰酰化的方法
WO2008075073A1 (en) 2006-12-21 2008-06-26 Astrazeneca Ab Novel crystalline compound useful as glk activator
ITMI20070435A1 (it) 2007-03-05 2008-09-06 Innovate Biotechnology Srl 2',3'-di-o-acil-5-fluoronucleosidi
BRPI0810067A2 (pt) * 2007-04-20 2014-10-21 Reddys Lab Ltd Dr Processo para a preparação de capecitabina
EP2164856A1 (en) * 2007-06-01 2010-03-24 Synthon B.V. Processes related to making capecitabine
WO2009042064A2 (en) 2007-09-21 2009-04-02 Nektar Therapeutics Al, Corporation Oligomer-nucleoside phosphate conjugates
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
WO2009088989A1 (en) * 2008-01-03 2009-07-16 Plus Chemicals, S.A. Process for the preparation of capecitabine
CN102641270A (zh) 2008-06-17 2012-08-22 惠氏有限责任公司 含有hki-272和长春瑞滨的抗肿瘤组合
HUE032958T2 (hu) 2008-08-04 2017-11-28 Wyeth Llc 4-Anilino-3-ciano-kinolinok és capecitabin antineoplasztikus kombinációi
EP2324028A2 (en) 2008-08-04 2011-05-25 AstraZeneca AB Therapeutic agents 414
WO2010065586A2 (en) * 2008-12-02 2010-06-10 Dr. Reddy's Laboratories Ltd. Preparation of capecitabine
EP2393472B1 (en) * 2008-12-05 2019-06-05 NanoMed Holdings Pty Ltd Amphiphile prodrugs
CN101787066B (zh) * 2009-01-23 2013-07-31 高峰 阿糖胞苷衍生物及其在抗癌抗肿瘤中的用途
GB0902434D0 (en) 2009-02-13 2009-04-01 Astrazeneca Ab Chemical process
GB0902406D0 (en) 2009-02-13 2009-04-01 Astrazeneca Ab Crystalline polymorphic form
LT3000467T (lt) 2009-04-06 2023-04-11 Wyeth Llc Krūties vėžio gydymo schema naudojant neratinibą
AR076221A1 (es) * 2009-04-09 2011-05-26 Astrazeneca Ab Derivado de pirazol [4,5-e] pirimidina y su uso para tratar diabetes y obesidad
WO2010116177A1 (en) 2009-04-09 2010-10-14 Astrazeneca Ab A pyrazolo [4,5-e] pyrimidine derivative and its use to treat diabetes and obesity
CN101875680B (zh) * 2009-04-28 2012-07-25 上海信旗医药科技有限公司 一种核苷类化合物及其制备方法和应用
KR20120037932A (ko) * 2009-07-23 2012-04-20 시노팜 타이완 리미티드 플루오로시티딘 유도체를 제조하는 방법
PL3117709T3 (pl) 2010-03-12 2019-01-31 Genzyme Corporation Terapia skojarzona do leczenia raka piersi
HK1206601A1 (en) 2012-04-02 2016-01-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
CN104411338A (zh) 2012-04-02 2015-03-11 现代治疗公司 用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸
EP2900657B1 (en) * 2012-09-26 2020-03-11 F.Hoffmann-La Roche Ag Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
CA2890359A1 (en) * 2012-11-07 2014-05-15 Zucai SUO Substituted gemcitabine aryl amide analogs and treatment methods using same
EP2971033B8 (en) 2013-03-15 2019-07-10 ModernaTX, Inc. Manufacturing methods for production of rna transcripts
US10000521B2 (en) 2013-03-15 2018-06-19 Nucorion Pharmaceuticals, Inc. Substituted gemcitabine bicyclic amide analogs and treatment methods using same
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
US20160194625A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Chimeric polynucleotides
CN103450301B (zh) * 2013-09-09 2015-09-09 南通大学 法尼基硫代水杨酸-核苷缀合物、其制备方法及其医药用途
WO2015051214A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
CN109414438A (zh) * 2016-06-28 2019-03-01 塞尔利克斯生物私人有限公司 用于治疗癌症的组合物和方法
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
WO2018129533A1 (en) 2017-01-09 2018-07-12 Shuttle Pharmaceuticals, Llc Selective histone deacetylase inhibitors for the treatment of human disease
CA3061621A1 (en) 2017-04-26 2018-11-01 Thomas I. Kalman Multitargeted nucleoside derivatives
US10435429B2 (en) 2017-10-03 2019-10-08 Nucorion Pharmaceuticals, Inc. 5-fluorouridine monophosphate cyclic triester compounds
US11407723B2 (en) 2018-01-09 2022-08-09 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
EP3752511A4 (en) 2018-01-10 2021-12-29 Nucorion Pharmaceuticals, Inc. Phosphor(n)amidatacetal and phosph(on)atalcetal compounds
US11427550B2 (en) 2018-01-19 2022-08-30 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds
CN111801339B (zh) * 2018-01-19 2025-06-24 纽科利制药公司 5-氟尿嘧啶化合物
US20210171564A1 (en) * 2018-08-03 2021-06-10 Cellix Bio Provate Limited Compositions and methods for the treatment of cancer
CN109651467A (zh) * 2019-01-15 2019-04-19 齐鲁天和惠世制药有限公司 一种卡培他滨杂质及其制备方法
MX2022000573A (es) 2019-07-17 2022-02-10 Nucorion Pharmaceuticals Inc Compuestos ciclicos de desoxirribonucleotido.
KR20230004716A (ko) 2020-04-21 2023-01-06 리간드 파마슈티칼스 인코포레이티드 뉴클레오티드 프로드러그 화합물
JP2023535225A (ja) 2020-07-24 2023-08-16 ストランド セラピューティクス インコーポレイテッド 改変ヌクレオチドを含む脂質ナノ粒子
MX2023008002A (es) 2021-01-08 2023-08-25 Constructos de expresion y usos de estos.
IL316186A (en) 2022-04-26 2024-12-01 Strand Therapeutics Inc Lipid nanoparticles containing Venezuelan equine encephalitis (VEE) replicon and uses thereof
WO2025193628A2 (en) 2024-03-09 2025-09-18 Aadigen, Llc Compositions for treating cancer with kras mutations and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3404144A (en) * 1965-12-23 1968-10-01 Research Corp 1-beta-d-arabinofuranosyl-5-fluorocytosine compounds
GB1379410A (en) * 1971-06-08 1975-01-02 Upjohn Co 1-beta-d-arabino-furanosyl-n4-alpha-aminoacylcytosines
JPS52153977A (en) * 1976-06-11 1977-12-21 Daikin Ind Ltd Synthesis of 5-fluorouracil and its derivatives
US4071680A (en) * 1976-12-20 1978-01-31 Hoffmann-La Roche Inc. 5'-Deoxy-5-fluoropyrimidine nucleosides
CH633810A5 (en) * 1978-01-01 1982-12-31 Hoffmann La Roche Novel nucleosides and process for their preparation
FR2528311B1 (fr) * 1982-06-14 1985-06-14 Synthelabo Compositions pharmaceutiques a base de xylosides et lyxosides de bases puriques et pyrimidiques
JPS61112093A (ja) * 1984-11-05 1986-05-30 Wakunaga Seiyaku Kk ヌクレオチド誘導体

Also Published As

Publication number Publication date
DE3854148D1 (de) 1995-08-17
DK640388D0 (da) 1988-11-16
FI89804C (fi) 1993-11-25
EP0316704A2 (de) 1989-05-24
LU90769I2 (fr) 2001-07-02
JPH01153696A (ja) 1989-06-15
NO171167C (no) 1993-02-03
GR3017686T3 (en) 1996-01-31
NO2001013I2 (no) 2006-05-01
US4966891A (en) 1990-10-30
AU619220B2 (en) 1992-01-23
KR890008162A (ko) 1989-07-10
PT89009B (pt) 1993-02-26
NZ226923A (en) 1990-10-26
AU2516888A (en) 1989-05-25
DK170893B1 (da) 1996-03-04
LT2185B (lt) 1993-10-15
PH25641A (en) 1991-08-21
CA1327358C (en) 1994-03-01
HU199866B (en) 1990-03-28
ZA888428B (en) 1989-06-28
DK640388A (da) 1989-05-18
LV5624A3 (lv) 1994-05-10
MC1992A1 (fr) 1989-11-30
HUT48267A (en) 1989-05-29
EP0316704A3 (en) 1990-11-22
NL300045I1 (nl) 2001-08-01
FI885329L (fi) 1989-05-18
DZ1270A1 (fr) 2004-09-13
FI885329A0 (fi) 1988-11-17
MX173347B (es) 1994-01-03
AR247217A1 (es) 1994-11-30
KR970000241B1 (ko) 1997-01-08
NL300045I2 (nl) 2002-01-02
IL88363A0 (en) 1989-06-30
CS747588A2 (en) 1990-09-12
IS3412A7 (is) 1989-05-18
IS1895B (is) 2003-10-20
EP0316704B1 (de) 1995-07-12
DE10199027I1 (de) 2001-08-02
CN1022688C (zh) 1993-11-10
YU209188A (en) 1990-08-31
ES2074429T3 (es) 1995-09-16
IE883430L (en) 1989-05-17
NO885106D0 (no) 1988-11-16
HK1003114A1 (en) 1998-10-09
CS274486B2 (en) 1991-04-11
SU1736342A3 (ru) 1992-05-23
DE10199027I2 (de) 2002-01-31
MX13836A (es) 1993-10-01
PT89009A (pt) 1988-12-01
NO885106L (no) 1989-05-18
CN1033183A (zh) 1989-05-31
UA19333A (uk) 1997-12-25
ATE124951T1 (de) 1995-07-15
JPH0678350B2 (ja) 1994-10-05
NO171167B (no) 1992-10-26
FI89804B (fi) 1993-08-13

Similar Documents

Publication Publication Date Title
YU47122B (sh) 5-deoksi-5-fluorocitidinski derivati
ATE74134T1 (de) Rapamycin-vorlaeufer.
NO163819C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 1h-imidazo(4,5-c)kinolin og derivater derav.
DK235690D0 (da) Platin(ii)-komplekser, deres fremstilling og anvendelse som antitumormidler
ES433902A1 (es) Procedimiento para la preparacion de bencilaminas.
ES8507090A1 (es) Procedimiento para la obtencion de nuevas 1, 5-benzotiacepinas
ES8704933A1 (es) Procedimiento para la obtencion de nuevos compuestos de piridazinio
DK391182A (da) Heterocycliske forbindelser, deres fremstilling og anvendelse
IL90559A0 (en) Analgetic derivatives of phenothiazine
MY109714A (en) Process for preparing 8-chloroquinolone derivatives
ES8607265A1 (es) Un procedimiento para la preparacion de nuevos derivados de aminoalcoholes
DE3870468D1 (de) Ergolinylheterocyclen.
ES8400743A1 (es) "procedimiento para la preparacion de compuestos de 1-fenilindazol-3-ona".
EP0134112A3 (en) Pharmaceutical composition for prophylaxis or treatment of ketosis in livestock
AU597923B2 (en) 5-aminoalkyl-beta-carboline derivatives, their production and their use as drugs
HUT60261A (en) Process for producing piperazine derivatives and pharmaceutical compositions comprising same
ES481872A1 (es) Un procedimiento para la preparacion de derivados del 3-azo-biciclo (3.1.0) hexano.
ZA894399B (en) New derivatives of phenothiazine,their preparation and the compositions which contain them
DE3271277D1 (en) Tropyl and pseudotropyl alkyl-benzoates and their use in migraine treatment
ES395496A1 (es) Procedimiento para la obtencion de derivados de 4-(3-amino-propoxi) indol.
BG50501A3 (bg) Метод за получаване на 1,5-бензтиазепинови производни